Home > Compound List > Compound details
212141-51-0 molecular structure
click picture or here to close

N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine dihydrochloride

ChemBase ID: 72509
Molecular Formular: C20H17Cl3N4
Molecular Mass: 419.73478
Monoisotopic Mass: 418.0518796
SMILES and InChIs

SMILES:
c1ccc2c(c1)c(nnc2Cc1ccncc1)Nc1ccc(cc1)Cl.Cl.Cl
Canonical SMILES:
Clc1ccc(cc1)Nc1nnc(c2c1cccc2)Cc1ccncc1.Cl.Cl
InChI:
InChI=1S/C20H15ClN4.2ClH/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14;;/h1-12H,13H2,(H,23,25);2*1H
InChIKey:
AZUQEHCMDUSRLH-UHFFFAOYSA-N

Cite this record

CBID:72509 http://www.chembase.cn/molecule-72509.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine dihydrochloride
IUPAC Traditional name
vatalanib dihydrochloride
Synonyms
Vatalanib succinate
PTK/ZK
CGP-79787D
CGP-79787
Vatalanib
CAS Number
212141-51-0
PubChem SID
162037434
PubChem CID
22386467

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price
Selleck Chemicals
S1101 external link Add to cart Please log in.
Data Source Data ID
PubChem 22386467 external link

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem
Acid pKa 15.168063  H Acceptors
H Donor LogD (pH = 5.5) 4.056382 
LogD (pH = 7.4) 4.1503754  Log P 4.151746 
Molar Refractivity 100.9756 cm3 Polarizability 39.110725 Å3
Polar Surface Area 50.7 Å2 Rotatable Bonds
Lipinski's Rule of Five true 

PROPERTIES

PROPERTIES

Physical Property Safety Information Pharmacology Properties Product Information Bioassay(PubChem)
Solubility
DMSO expand Show data source
Storage Condition
-20°C expand Show data source
Target
c-Kit expand Show data source
FLK expand Show data source
Flt expand Show data source
VEGFR expand Show data source
Salt Data
Dihydrochloride expand Show data source

DETAILS

DETAILS

Selleck Chemicals Selleck Chemicals
Selleck Chemicals - S1101 external link
Research Area
Description Cancer
Biological Activity
Description Vatalanib (PTK787) is a VEGFR inhibitor of KDR and Flt-1 with IC50 of 37 nM and 77 nM, respectively.
Targets KDR Flt-1
IC50 37 nM 77 nM [1]
In Vitro Vatalanib also inhibits Flk, c-Kit and PDGFRβ with IC50 of 270 nM, 730 nM and 580 nM, respectively. Furthermore, Vatalanib shows the anti-proliferation effect by inhibiting thymidine incorporation induced by VEGF in HUVECs with and IC50 of 7.1 nM, and dose-dependently suppresses VEGF-induced survival and migration of endothelial cells in the same dose range without cytotoxic or antiproliferative effect on cells that do not express VEGF receptors. [1] A recent study shows that Vatalanib significantly inhibits the growth of hepatocellular carcinoma cells and enhances the IFN/5-FU induced apoptosis by increasing proteins levels of Bax and reduced Bcl-xL and Bcl-2. [2]
In Vivo Vatalanib induces dose-dependent inhibition of the angiogenic response to VEGF and PDGF in both a growth factor implant model and a tumor cell-driven angiogenesis model after once-daily oral dosing (25-100 mg/kg). In the same dose range, Vatalanib also inhibits the growth and metastasesof several human carcinomas in nude mice without significant effect on circulating blood cells or bone marrow leukocytes. [1]
Clinical Trials Vatalanib is currently in Phase II clinical trials in patients with Metastatic Neuroendocrine Tumors.
Features
Protocol
Kinase Assay [1]
VEGF Receptor Tyrosine Kinase Assays The in vitro kinase assays are performed in 96-well plates as a filter binding assay, using the recombinant GST-fused kinase domains expressed in baculovirus and purified over glutathione-Sepharose. γ-[33P]ATP is used as the phosphate donor, and poly-(Glu:Tyr 4:1) peptide is used as the acceptor. Recombinant GST-fusion proteins are diluted in 20 mM Tris·HCl (pH 7.5) containing 1–3 mM MnCl2, 3–10 mM MgCl2, 0.25 mg/mL polyethylene glycol 20000, and 1 mM DTT, according to their specific activity. Each GST-fused kinase is incubated under optimized buffer conditions [20 mM Tris-HCl buffer (pH 7.5), 1–3 mM MnCl2, 3–10 mM MgCl2, 3–8 μg/mL poly-(Glu:Tyr 4:1), 0.25 mg/mL polyethylene glycol 20000, 8 μM ATP, 10 μM sodium vanadate, 1 mM DTT, and 0.2 μCi[γ-33P]ATP in a total volume of 30 μL in the presence or absence of a test substance for 10 minutes at ambient temperature. The reaction is stopped by adding 10 μL of 250 mM EDTA. Using a 96-well filter system, half the volume (20 μL) is transferred onto a Immobilon-polyvinylidene difluoride membrane. The membrane is then washed extensively in 0.5% H3PO4 and then soaked in ethanol. After drying, Microscint cocktail is added, and scintillation counting is performed. IC50s for PTK787/ZK 222584 or SU5416 in these as well as all assays described below are calculated by linear regression analysis of the percentage inhibition.
Cell Assay [1]
Cell Lines HUVECs
Concentrations 0-10 μM
Incubation Time 48 hours
Methods As a test of the ability of PTK787/ZK 222584 to inhibit a functional response to VEGF, an endothelial cell proliferation assay, based on BrdUrd incorporation is used. Subconfluent HUVECs are seeded into 96-well plates coated with 1.5% gelatin and then incubated at 37 °C and 5% CO2 in growth medium. After 24 hours, growth medium is replaced by basal medium containing 1.5% FCS and a constant concentration of VEGF (50 ng/mL), bFGF (0.5 ng/mL), or FCS (5%), in the presence or absence of PTK787/ZK 222584. As a control, wells without growth factor are also included. After 24 hours of incubation, BrdUrd labeling solution is added, and cells incubated an additional 24 hours before fixation, blocking, and addition of peroxidase-labeled anti-BrdUrd antibody. Bound antibody is then detected using 3,3′5,5′-tetramethylbenzidine substrate, which results in a colored reaction product that is quantified spectrophotometrically at 450 nm.
Animal Study [1]
Animal Models A431 epithelial carcinoma, Ls174T colon carcinoma, HT-29 colon carcinoma, PC-3 prostate carcinoma, DU145 prostate carcinoma, and CWR-22 prostate carcinoma cells are injected s.c. into the nude mice.
Formulation Vatalanib is dissolved in distilled water containing 5% DMSO and 1% Tween 80.
Doses 25-100 mg/kg
Administration Administered via p.o.
References
[1] Wood JM, et al. Cancer Res. 2000, 60(8), 2178-2189.
[2] Murakami M, et al. Ann Surg Oncol. 2011, 18(2), 589-596.

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle